Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Float looks to be locked up. Glad I got more the last couple days. I'm looking for a dollar here or possibly more. Billion dollar opportunity they have with there products if approved
L2 getting thin on the way up. People are starting to hold and make people pay higher prices.. Here we go.
Same here. I got in at .022 and also been buying on the dips averaging up. This is a great company and shareholders will be rewarded in my opinion.
I need to get 1 million shares:)
Same here. I may sell a little bit at $2.00 but hold the rest. I have 50k shares for my daughter to hold for 18 years. :)
I think we can hit 1.00 or 3.00. . This is a billion dollar opportunity
Wtih positive data and float LOCKED this can go to $1 or more. Lets wait and see :)
Its seems the float is getting locked up here plus the company may be buying up all the outstanding shares. Glad i got my shares. This is going to be a fun ride. Glad to be here with everybody.
Man when we get news GIGL is going to be moving Fast and onward. It will be crazy. It would be awesome to get news they agree on 5 new locations with a 1.4 million LOI for all of them wouldn't it. :) Can't believe people are even selling. Oh well people that aren't patient will never make much money anyway.
I loaded the rest of my shares. :). Thank you mm
Good morning. Man. Looking forward the Day and weeks ahead with this one. I think this Stock and company will be one of the best this year in the OTC then of course BB.
$ENDV$ DD BELOW. Multi Dollars ahead . If you can't see the writing on the wall then you don't deserve to be in this stock or part of this company when it is Trading
at Multi dollars.
https://www.otcmarkets.com/stock/ENDV/news
ENDV Security Details (GREAT SHARE STRUCTURE) COMPANY IS LOCKING UP FLOAT>
Share Structure
Market Value1 $4,827,068 a/o Mar 10, 2017
Authorized Shares
500,000,000 a/o Mar 07, 2017
Outstanding Shares
155,711,859 a/o Mar 07, 2017
-Restricted 101,250,828 a/o Mar 07, 2017
-Unrestricted 54,461,031 a/o Mar 07, 2017
Held at DTC 34,692,700 a/o Mar 07, 2017
Float 622,092 a/o May 18, 2015
Par Value Not Available
Transfer Agent(s) Verified by Transfer Agent
ClearTrust, LLC
Shareholders
Shareholders of Record 317 a/o May 17, 2016
AWESOME NEWS BELOW>
Endonovo Signs Term Sheet for $5 Million to Redeem All Outstanding Convertible Notes and Prepare to Uplist Its Common Stock
Financing to be Used for the Development of a Portfolio of Treatments for Vascular Diseases and Ischemic Injuries Using Endonovo's Immunotronics Platform
LOS ANGELES, CA--(Marketwired - Nov 28, 2016) - Endonovo Therapeutics, Inc. (OTCQB: ENDV) ("Endonovo" or the "Company"), a developer of non-invasive electroceuticals for the treatment of inflammatory conditions and diseases in vital organs, today announced that it has signed a term sheet with a single strategic healthcare investor for $5 million in Series B Preferred Stock financing to redeem all of its outstanding convertible notes, fund several pre-clinical studies targeting vascular diseases and ischemic injuries in vital organs and to prepare to uplist the Company's common stock onto a national stock exchange.
The financing, subject to the signing of a definitive agreement, will be used to buy back approximately $2.2 million in Company convertible notes in order to preserve shareholder value, prevent additional dilution from the conversion of notes payable and to strengthen the Company's balance sheet. The strategic healthcare investor is serving as lead investor in a larger $15 million proposed financing to uplist the Company's common stock onto a national stock exchange in the first half of 2017.
Additionally, Endonovo plans to use the proceeds from the financing to fund the development of a portfolio of treatments for vascular diseases, including critical limb ischemia and ischemic ulcers, as well as treatments targeting vascular ischemia and reperfusion injuries in vital organs, including the liver, heart, kidneys, and central nervous system using the Company's non-invasive Immunotronicsâ„¢ platform. The Company is preparing to conduct the first of several pre-clinical trials in the first quarter of 2017.
The Company's Immunotronicsâ„¢ platform, which uses time variant magnetic pulses to illicit anti-inflammatory responses in cells and tissues and promotes tissue regeneration, has demonstrated significant potential in pre-clinical studies of acute inflammation and bone regeneration. Endonovo is now developing its Immunotronicsâ„¢ platform to target inflammatory conditions in vital organs and for regenerative medicine.
"We are very excited to work with a strategic investor, who recognizes the value of the Company and the significant potential of our non-invasive technology in the treatment of several very large unmet clinical needs," stated Endonovo Chairman and CEO Alan Collier.
"It is very important that we buy back all outstanding convertible notes in order to prevent dilution and preserve shareholder value. We believe that our stock is considerably undervalued," continued Mr. Collier.
"This round of financing allows us to fund our the development of portfolio of treatments targeting vascular diseases and ischemic injuries and strengthens our financial position to uplist our common stock onto a national stock exchange in the first half of next year," concluded Mr. Collier.
I would like to get 500k total so actually i would like it to go down so i can get more but i have a feeling it won't go down much or at all so im just going to get what i can at this point . If people cant see the writing on the wall then it is there deal. I have done DD
I would be nice to get more shares. But if this does get the node from the FDA there wont' be any filling the gap man. Im just getting as many share as i can afford under the .10 cent range :)
$ENDV$ ICLD looking good. Whats everyone think about ENDV> Check out all DD over there as well. Riding a good way here. GReat DD and a blessing to be in this one with you guys.
L2 is looking crazy right now. We may be to $1.00 sooner than i thought. Glad I got in this and not flipping this for sure. Alot of Solid DD here. Check it out. Company buying up all float and planning on uplisting.
Ask Price
Size
Date/Time
VNDM 0.07 10,000 03/13
ARCA 0.1419 17,100 08:00
NITE 0.17 5,000 08:04
CSTI 0.17 5,000 08:30
ARXS 0.2685 2,500 03/13
CANT 0.32 2,500 08:30
BMAK 8.00 100 08/24
MAXM 8.00 100 08:02
cVFIN 0.045 10,000 03/13
CDEL U 0 06:46
cETRF U 0 08:36
I think it was toxic financing. They got that cleared up with the funding through an investor . Look at the PR. I think we found a gem here. A lot of solid DD
They aren't allowed to tell anybody anything until it come public per sec. :)
SUNNY how is it going? I posted a play on your board. It is ENDV. I really do this this is a great long term play and possible dollar land stock. What is your thought. Im in with you on ICLD. I think im going to take some profits and buy some ENDV. Just thought i would let you know before it possibly takes off
$ENDV$ DD BELOW. Multi Dollars ahead . If you can't see the writing on the wall then you don't deserve to be in this stock or part of this company when it is Trading at Multi dollars.
https://www.otcmarkets.com/stock/ENDV/news
ENDV Security Details (GREAT SHARE STRUCTURE) COMPANY IS LOCKING UP FLOAT>
Share Structure
Market Value1 $4,827,068 a/o Mar 10, 2017
Authorized Shares 500,000,000 a/o Mar 07, 2017
Outstanding Shares 155,711,859 a/o Mar 07, 2017
-Restricted 101,250,828 a/o Mar 07, 2017
-Unrestricted 54,461,031 a/o Mar 07, 2017
Held at DTC 34,692,700 a/o Mar 07, 2017
Float 622,092 a/o May 18, 2015
Par Value Not Available
Transfer Agent(s) Verified by Transfer Agent
ClearTrust, LLC
Shareholders
Shareholders of Record 317 a/o May 17, 2016
AWESOME NEWS BELOW>
Endonovo Signs Term Sheet for $5 Million to Redeem All Outstanding Convertible Notes and Prepare to Uplist Its Common Stock
Financing to be Used for the Development of a Portfolio of Treatments for Vascular Diseases and Ischemic Injuries Using Endonovo's Immunotronics Platform
LOS ANGELES, CA--(Marketwired - Nov 28, 2016) - Endonovo Therapeutics, Inc. (OTCQB: ENDV) ("Endonovo" or the "Company"), a developer of non-invasive electroceuticals for the treatment of inflammatory conditions and diseases in vital organs, today announced that it has signed a term sheet with a single strategic healthcare investor for $5 million in Series B Preferred Stock financing to redeem all of its outstanding convertible notes, fund several pre-clinical studies targeting vascular diseases and ischemic injuries in vital organs and to prepare to uplist the Company's common stock onto a national stock exchange.
The financing, subject to the signing of a definitive agreement, will be used to buy back approximately $2.2 million in Company convertible notes in order to preserve shareholder value, prevent additional dilution from the conversion of notes payable and to strengthen the Company's balance sheet. The strategic healthcare investor is serving as lead investor in a larger $15 million proposed financing to uplist the Company's common stock onto a national stock exchange in the first half of 2017.
Additionally, Endonovo plans to use the proceeds from the financing to fund the development of a portfolio of treatments for vascular diseases, including critical limb ischemia and ischemic ulcers, as well as treatments targeting vascular ischemia and reperfusion injuries in vital organs, including the liver, heart, kidneys, and central nervous system using the Company's non-invasive Immunotronicsâ„¢ platform. The Company is preparing to conduct the first of several pre-clinical trials in the first quarter of 2017.
The Company's Immunotronicsâ„¢ platform, which uses time variant magnetic pulses to illicit anti-inflammatory responses in cells and tissues and promotes tissue regeneration, has demonstrated significant potential in pre-clinical studies of acute inflammation and bone regeneration. Endonovo is now developing its Immunotronicsâ„¢ platform to target inflammatory conditions in vital organs and for regenerative medicine.
"We are very excited to work with a strategic investor, who recognizes the value of the Company and the significant potential of our non-invasive technology in the treatment of several very large unmet clinical needs," stated Endonovo Chairman and CEO Alan Collier.
"It is very important that we buy back all outstanding convertible notes in order to prevent dilution and preserve shareholder value. We believe that our stock is considerably undervalued," continued Mr. Collier.
"This round of financing allows us to fund our the development of portfolio of treatments targeting vascular diseases and ischemic injuries and strengthens our financial position to uplist our common stock onto a national stock exchange in the first half of next year," concluded Mr. Collier.
Investor Relations Contact:
Endonovo Therapeutics, Inc.
Mr. Steven Barnes
Senior Vice President of Investor Relations
(800) 701-1223, Ext. 108
Sbarnes@endonovo.com
www.endonovo.com
$ENDV$ DD BELOW. Multi Dollars ahead . If you can't see the writing on the wall then you don't deserve to be in this stock or part of this company when it is Trading at Multi dollars.
https://www.otcmarkets.com/stock/ENDV/news
ENDV Security Details (GREAT SHARE STRUCTURE) COMPANY IS LOCKING UP FLOAT>
Share Structure
Market Value1 $4,827,068 a/o Mar 10, 2017
Authorized Shares 500,000,000 a/o Mar 07, 2017
Outstanding Shares 155,711,859 a/o Mar 07, 2017
-Restricted 101,250,828 a/o Mar 07, 2017
-Unrestricted 54,461,031 a/o Mar 07, 2017
Held at DTC 34,692,700 a/o Mar 07, 2017
Float 622,092 a/o May 18, 2015
Par Value Not Available
Transfer Agent(s) Verified by Transfer Agent
ClearTrust, LLC
Shareholders
Shareholders of Record 317 a/o May 17, 2016
AWESOME NEWS BELOW>
Endonovo Signs Term Sheet for $5 Million to Redeem All Outstanding Convertible Notes and Prepare to Uplist Its Common Stock
Financing to be Used for the Development of a Portfolio of Treatments for Vascular Diseases and Ischemic Injuries Using Endonovo's Immunotronics Platform
LOS ANGELES, CA--(Marketwired - Nov 28, 2016) - Endonovo Therapeutics, Inc. (OTCQB: ENDV) ("Endonovo" or the "Company"), a developer of non-invasive electroceuticals for the treatment of inflammatory conditions and diseases in vital organs, today announced that it has signed a term sheet with a single strategic healthcare investor for $5 million in Series B Preferred Stock financing to redeem all of its outstanding convertible notes, fund several pre-clinical studies targeting vascular diseases and ischemic injuries in vital organs and to prepare to uplist the Company's common stock onto a national stock exchange.
The financing, subject to the signing of a definitive agreement, will be used to buy back approximately $2.2 million in Company convertible notes in order to preserve shareholder value, prevent additional dilution from the conversion of notes payable and to strengthen the Company's balance sheet. The strategic healthcare investor is serving as lead investor in a larger $15 million proposed financing to uplist the Company's common stock onto a national stock exchange in the first half of 2017.
Additionally, Endonovo plans to use the proceeds from the financing to fund the development of a portfolio of treatments for vascular diseases, including critical limb ischemia and ischemic ulcers, as well as treatments targeting vascular ischemia and reperfusion injuries in vital organs, including the liver, heart, kidneys, and central nervous system using the Company's non-invasive Immunotronicsâ„¢ platform. The Company is preparing to conduct the first of several pre-clinical trials in the first quarter of 2017.
The Company's Immunotronicsâ„¢ platform, which uses time variant magnetic pulses to illicit anti-inflammatory responses in cells and tissues and promotes tissue regeneration, has demonstrated significant potential in pre-clinical studies of acute inflammation and bone regeneration. Endonovo is now developing its Immunotronicsâ„¢ platform to target inflammatory conditions in vital organs and for regenerative medicine.
"We are very excited to work with a strategic investor, who recognizes the value of the Company and the significant potential of our non-invasive technology in the treatment of several very large unmet clinical needs," stated Endonovo Chairman and CEO Alan Collier.
"It is very important that we buy back all outstanding convertible notes in order to prevent dilution and preserve shareholder value. We believe that our stock is considerably undervalued," continued Mr. Collier.
"This round of financing allows us to fund our the development of portfolio of treatments targeting vascular diseases and ischemic injuries and strengthens our financial position to uplist our common stock onto a national stock exchange in the first half of next year," concluded Mr. Collier.
Investor Relations Contact:
Endonovo Therapeutics, Inc.
Mr. Steven Barnes
Senior Vice President of Investor Relations
(800) 701-1223, Ext. 108
Sbarnes@endonovo.com
www.endonovo.com
Nice article. I've did alot of DD on this company this weekend. I loaded today and hope to kept adding on any dips. this could be huge or life changing for sure. Patients is the name of the game here. If it gets the NODE by the FDA im wondering what the price per share would be then. ? Any guesss
Take those .1225 out.
Me five. Add. On little dips. :)
Patients usually wins. Know what you own. Just added more on the dip.
I agree. I did a lot of DD this weekend. This may be a GEM here. I got in at .045 and .047 . These shares are getting locked up . It is hard to get shares in big blocks as well. This may be a once in a lifetime opportunity. I'm not pumping im just going off my DD.
I think we can get to $1 real quick here of course this is my opinion. What is everyones thought.
4 dollars would be nice. If they get FDA approval what is your target price
Shares are being locked up Company trying to get to BB that means 1.00 . Im in at .045
Long ENDV. If they get approval watch out. This will be above 1 or 2 dollars.
Good afternoon. Been doing some DD here. is there a chance we could hit .15 to .20 on this board?
I would like a giggles and hugs in Des moines
They are getting some attention. Watch chucky cheese try to buy these guys out or sometime big investor try to take over. 2 to 5 dollar buyout
Des moines
That sounds good to me. We would take a road trip up there. Only 2.5 hrs away from Des Moines iowa
That would be Iowa and Nebraska. Yes. Closer to me. :)
Hopefully Iowa or somewhere around Iowa so we can go for sure
I will be here. I'm hoping for Giggles&Hugs to come to Iowa. I would love to take are daughter there. We have long winters here.
Wow dude. That would be great for us
My daughters 50k shares for her college fund would look great. Plus my shares as well??
Agreed ??. Hopefully people realize this before they have to buy at 1.00. This is a once in a lifetime company for sure. The DD has the writing all over the wall
Nice post CommonCents. I feel exactly the same man. Slow and steady wins the race. Hope with a couple big jumps once in a while :)
$GIGL$ Yes because this will be worth multi dollars CHUCKY CHEESE is worth 1.3 billion dollars. That would put us at around $10.00 a share. What about a possible buy out if we start growing . There is alot on the plate right now.